Hepatocellular carcinoma is a common malignant tumor occurring in the liver. Patients diagnosed at an early stage can survive for 3-5 years if they choose surgical treatment in time. If patients with progressive and intermediate to advanced stages have local resection, they also need to combine adjuvant therapy, including targeted, immune and interventional therapy, etc., and the survival time also varies significantly. The occurrence of liver malignancy is also influenced by a variety of factors and has a certain family genetic predisposition. It is easy to develop hematogenous or intrahepatic metastases and abdominal lymph node metastases. Liver malignancies are also prone to complications of anemia and hypoproteinemia, and in later stages, they may also manifest as significant ascites, induce hepatic encephalopathy, and have a significantly shorter survival time. For patients with early diagnosis, they need to monitor the relevant laboratory indexes regularly after surgery to see the changes of tumor markers. There are many patients who need adjuvant treatment, and they should pay attention to dietary regimen and regularity of life in general.